Oncology in 2012: from personalized medicine to precision medicine J. F. Morere Editorial 22 November 2012 Pages: 211 - 212
Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2 Motohiro ImanoTakao SatouHitoshi Shiozaki Original Research 03 July 2012 Pages: 213 - 216
Anticancer role of MUC1 aptamer–miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation Furong DaiYi ZhangYuxiang Chen Original Research 20 November 2012 Pages: 217 - 225
Biosimilars and market access: a question of comparability and costs? Steven SimoensGilbert VerbekenIsabelle Huys Review 17 January 2012 Pages: 227 - 231
Hyperbaric oxygen therapy and cancer—a review Ingrid MoenLinda E. B. Stuhr Review Open access 02 October 2012 Pages: 233 - 242
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice Maristella SaponaraMaria Abbondanza PantaleoGuido Biasco Day-to-Day Practice 17 May 2012 Pages: 243 - 246
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma Thomas NeuhausJoachim Luyken Day-to-Day Practice 23 October 2012 Pages: 247 - 251
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial Christophe Le TourneauMaud KamalXavier Paoletti Perspectives 17 November 2012 Pages: 253 - 265
Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer Andrea Sartore-BianchiKatia BencardinoSalvatore Siena Erratum 29 June 2010 Pages: 267 - 267